drug: ziprasidone
- Clinical class: atypical antipsychotic
- Chemical class: benzisothiazolylpiperazine
- Action: serotonin-dopamine antagonist
- Active metabolite: none
- DEA schedule: none
- FDA Medwatch Consumer Advisory
- MEDLINEplus® Drug Information
U.S. Preparations:
- Geodon® Oral (Pfizer) FDA approved for treatment of: Schizophrenia 2.5.2001
- Geodon®
Injectable (Pfizer) FDA approved for treatment of: acute
agitation in schizophrenic patients for whom treatment with ziprasidone
is appropriate and who need intramuscular antipsychotic medication for rapid
control of the agitation 6.21.2002; acute
manic or
mixed episodes associated
with Bipolar Disorder, with or without
psychotic features 8.19.2004
U.S. Prescribing information
- Zeldox (Pfizer - FDA rejected this trade name.)
Stephen Stahl's Clinical Pearls* (Consult your physician before making any change in your treatment.)
- Little weight gain
- In addition to SDA pharmacology, unique binding properties include 5HT1A agonist, 5HT1D antagonist, 5HT2C antagonist, and serotonin and norepinephrine reuptake blockade.
- Unique pharmacologic profile suggests potential advantages for associated anxiety and depression.
- Early study reporting use in children ages 7-17 with Gilles de la Tourette syndrome in which it is well tolerated and effective
- Approved in Sweden, pending approval in the USA, and currently not marketed anywhere.
- Somnolence and dizziness are the most frequent side effects.
- Prolongs the mean QT interval slightly, with greater prolongations in some individuals.
- Significance of QT prolongations currently under investigation and will be resolved before approval in the USA.
| Books and Other Media: Follow the hypertext link to purchase items online. |
|
*Reprinted with permission from: Stahl, Stephen M Psychopharmacology of Antipsychotics Paperback 1999 Martin Dunitz, Ltd You cannot fully appreciate this book until you have seen the extraordinary illustrations of every aspect of this area of psychopharmacology and neurochemistry. Loaded with practical clinical "pearls."